Proactive Research analyst Emma Ulker says Open Orphan PLC (LON:ORPH) is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services.
She says with its hVIVO subsidiary now integrated, it's leveraging its capabilities to the full, growing the top line and targeting near term profitability by delivering specialist pharma services across its hVIVO and Venn subsidiaries.